Russell MS - Acumen Pharmaceuticals Chief Officer

Acumen Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3906) % which means that it has lost $0.3906 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7571) %, meaning that it created substantial loss on money invested by shareholders. Acumen Pharmaceuticals' management efficiency ratios could be used to measure how well Acumen Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.45 in 2025. Return On Capital Employed is likely to drop to -0.57 in 2025. At this time, Acumen Pharmaceuticals' Net Tangible Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 97.6 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 31.6 M in 2025.

Similar Executives

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimers disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Acumen Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. Acumen Pharmaceuticals (ABOS) is traded on NASDAQ Exchange in USA. It is located in 1210-1220 Washington St., Newton, MA, United States, 02465 and employs 61 people. Acumen Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Acumen Pharmaceuticals Leadership Team

Acumen Stock Performance Indicators

Additional Tools for Acumen Stock Analysis